Neurocrine Raises 2026 Ingrezza Sales Guidance to $2.9–$2.93 Billion
Neurocrine Biosciences raised its 2026 net sales guidance for Ingrezza to $2.9 billion–$2.93 billion, according to a filing with the SEC.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Neurocrine Biosciences told the SEC that it now expects 2026 net sales of Ingrezza to fall between $2.9 billion and $2.93 billion. The company also reported third-quarter 2026 results, with non-GAAP earnings of $3.29 per share.
Revenue rose 41% year over year to $1.10 billion in the quarter. Ingrezza net product sales alone reached $801 million in the third quarter, up 17% from a year earlier.
why it matters
For investors, this signals that the company's main product is growing noticeably faster than a year ago. Guidance increases like this are typically weighed when valuing biotech stocks, though the filing says nothing about how the market reacted.
market impact
Neurocrine shares: higher guidance and revenue growth support the stock
- Neurocrine Biosciences shares pressure up — higher sales guidance and 41% revenue growth support the stock
tags
instruments
sources
- Neurocrine Biosciences - Ingrezza 2026 Net Sales Guidance Raised To $2.9 Billion-$2.93 Billion — SEC Filing, 2 November 2026 at 22:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗